Norwegian version of this page

Securing high-quality Care For Cancer patients at End-of-life – The SAFE-study

Through the SAFE-study, we will contribute to new knowledge on care in cancer patients’ end-of-life, by describing, understanding and evaluating care pathways.

Model: The SAFE-study

Model: SAFE. Describing end-of-life pathways. Understanding preferences for end-of-life care. Registry-based study: Using real world data (RWD). Qualitative study: Interviews of patients, informal caregivers and formal caregivers. Cross-sectional study: Comparing ICECAP and EQ-5D-5L.

Cancer patients are heterogeneous, with regard to severity, age, gender, comorbidity and access to informal care givers. To enable home-based care and death, care provision focuses on interdisciplinary and integrated care, including secondary, primary and home and community-based care givers, in addition to informal carers. Consequently, end-of-life care is complex and resource demanding with an estimated annual cost to the healthcare sector of NOK 4.4 billion. Despite this, little knowledge exists on (1) composition of care to cancer patients end-of-life, (2) perception among care providers, patients and informal caregivers of the content of safe, high-quality end-of-life care.

News

Objectives

The primary objective of the SAFE-study is to increase the likelihood for cancer patients to receive safe, high-quality end-of-life care.

Sub-projects

1) describe current care pathway of cancer patients, and identify the role of informal care and heterogeneity,

2) understand how patients, informal caregivers and formal care providers perceive high quality end-of-life care, and understand which factors influence patients and their next of kinds’ health-related quality of life (HRQoL). We will compare ICECAP and EQ-5D-5L.

Financing

Norwegian Cancer Society.

Cooperation

Deakin University (Australia),University of Turku (Finland), Moss Municipality, Stange Municipality

Project Start and Finish

July 2020 to Dec 2023

 

Published Sep. 8, 2020 11:45 AM - Last modified Sep. 19, 2022 8:51 AM

Participants

  • Eline Aas Universitetet i Oslo
  • Gudrun Maria Waaler Bjørnelv Universitetet i Oslo
  • Lisbeth Thoresen Universitetet i Oslo
  • Terje P. Hagen Universitetet i Oslo
  • Nikki McCaffery (Deakin University)
  • Lidia Engel (Deakin University)
  • Leena Forma (University of Turku)
  • Eli Thomassen (Moss Municipality)
  • Unn Torill Tveitane (Stange Municipality)
  • Yvonne Michel (Norwegian Medicines Agency)
  • Nina Løkkevik (Moss municipality)
Detailed list of participants